Posted inDiabetes & Endocrinology news Specialties
Tirzepatide Significantly Lowers Predicted 10-Year Type 2 Diabetes Risk in Chinese Adults with Overweight or Obesity: Insights from the SURMOUNT-CN Trial
Post hoc analysis of the SURMOUNT-CN trial shows tirzepatide markedly reduces the 10-year predicted risk of type 2 diabetes in Chinese individuals with overweight or obesity, regardless of baseline BMI or prediabetes status.